Quick Answer
Axsome Therapeutics, Inc. reported Cash and Equivalents of $322.93 million for fiscal year 2025.
Axsome Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $322.93M | +2.4% |
| 2024 | $315.35M | -18.3% |
| 2023 | $386.19M | +92.3% |
| 2022 | $200.84M | +132.3% |
| 2021 | $86.47M | -53.0% |
| 2020 | $183.88M | -16.4% |
| 2019 | $219.97M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $325.27M | -0.6% | +7.3% |
| June 30, 2025 | $303.02M | -4.0% | +0.7% |
| March 31, 2025 | $300.91M | -9.2% | -4.6% |
| December 31, 2024 | $315.35M | -18.3% | -3.7% |
| September 30, 2024 | $327.34M | -21.4% | +3.7% |
| June 30, 2024 | $315.66M | -27.8% | -4.8% |
| March 31, 2024 | $331.44M | +34.5% | -14.2% |
| December 31, 2023 | $386.19M | +92.3% | -7.3% |
- Axsome Therapeutics, Inc. showed an increase of +2.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Axsome Therapeutics, Inc.’s cash and equivalents has grown by 46.8% (from $219.97 million to $322.93 million).
- The most recent figure is from Axsome Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: